Medicines by demand
Medicines by Medicare Part D demand: the dated federal facts we hold
Medicines that are not in the CMS negotiation file but rank high in Medicare Part D spending. These pages carry no negotiated price because none exists; they show what the federal files do record. Looking for negotiated drugs? See the negotiated drugs pages.
The medicines
Demand rank orders drugs by the summed Medicare Part D gross spending of the names CMS reports each one under. Basis: CMS Medicare Part D Spending by Drug, 2024 Overall rows, ranked by total spending (figures do not reflect manufacturer rebates); a demand proxy, not a measure of need. Spending is a demand proxy and is not a patient price.
| Medicine | Demand rank | Ingredient | Part D gross spending | Layers with facts |
|---|---|---|---|---|
| Mounjaro | 4 | tirzepatide | $6.34 billion (2024) | FDA application facts, assistance programs, Medicaid spending, federal formularies |
| Humira | 6 | adalimumab | $5.64 billion (2024) | FDA application facts, recalls, assistance programs, biosimilar status, Medicaid spending, federal formularies |
| Revlimid | 10 | lenalidomide | $4.18 billion (2024) | FDA application facts, recalls, Medicaid spending, federal formularies |
| Vyndamax | 17 | tafamidis | $2.83 billion (2024) | FDA application facts, Medicaid spending, federal formularies |
| Dupixent | 19 | dupilumab | $2.49 billion (2024) | FDA application facts, recalls, assistance programs, biosimilar status, Medicaid spending, federal formularies |
| Skyrizi | 20 | risankizumab-rzaa | $2.49 billion (2024) | FDA application facts, biosimilar status, Part B payment limit, Medicaid spending, federal formularies |
| Myrbetriq | 21 | mirabegron | $2.30 billion (2024) | FDA application facts, Medicaid spending, federal formularies |
| Jakafi | 25 | ruxolitinib | $2.08 billion (2024) | FDA application facts, Medicaid spending, federal formularies |
| Ingrezza | 28 | valbenazine | $1.96 billion (2024) | FDA application facts, Medicaid spending, federal formularies |
| Repatha | 29 | evolocumab | $1.91 billion (2024) | FDA application facts, assistance programs, biosimilar status, Medicaid spending, federal formularies |
| Invega Sustenna | 31 | paliperidone palmitate | $1.88 billion (2024) | FDA application facts, Part B payment limit, Medicaid spending |
| Tresiba | 32 | insulin degludec | $1.80 billion (2024) | FDA application facts, recalls, assistance programs, biosimilar status, Medicaid spending, federal formularies |
| Brukinsa | 33 | zanubrutinib | $1.72 billion (2024) | FDA application facts, Medicaid spending, federal formularies |
| Tagrisso | 35 | osimertinib | $1.63 billion (2024) | FDA application facts, Medicaid spending, federal formularies |
| Rinvoq | 39 | upadacitinib | $1.39 billion (2024) | FDA application facts, assistance programs, Medicaid spending, federal formularies |
| Restasis | 41 | cyclosporine | $1.29 billion (2024) | FDA application facts, Medicaid spending, federal formularies |
| Opsumit | 42 | macitentan | $1.23 billion (2024) | FDA application facts, Medicaid spending, federal formularies |
| Cabometyx | 43 | cabozantinib | $1.22 billion (2024) | FDA application facts, Medicaid spending, federal formularies |
| Toujeo | 48 | insulin glargine | $1.11 billion (2024) | FDA application facts, assistance programs, biosimilar status, Medicaid spending |
| Nubeqa | 52 | darolutamide | $998.07 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Gemtesa | 53 | vibegron | $945.09 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Venclexta | 54 | venetoclax | $941.72 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Uptravi | 55 | selexipag | $908.77 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Spiriva Respimat | 56 | tiotropium bromide inhalation spray | $877.21 million (2024) | FDA application facts, assistance programs, Medicaid spending, federal formularies |
| Lantus | 59 | insulin glargine | $839.03 million (2024) | FDA application facts, assistance programs, biosimilar status, Medicaid spending, federal formularies |
| Prolia | 64 | denosumab | $771.84 million (2024) | FDA application facts, recalls, biosimilar status, Part B payment limit, Medicaid spending, federal formularies |
| Tyvaso Dpi | 68 | treprostinil | $728.75 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Vascepa | 70 | icosapent ethyl | $724.18 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Oxervate | 71 | cenegermin-bkbj | $714.55 million (2024) | FDA application facts, biosimilar status, Medicaid spending, federal formularies |
| Adempas | 73 | riociguat | $694.25 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Brilinta | 75 | ticagrelor | $685.50 million (2024) | FDA application facts, recalls, Medicaid spending, federal formularies |
| Promacta | 76 | eltrombopag olamine | $672.38 million (2024) | FDA application facts, recalls, Medicaid spending |
| Basaglar | 77 | insulin glargine | $664.63 million (2024) | FDA application facts, assistance programs, biosimilar status, Medicaid spending, federal formularies |
| Humalog | 78 | insulin lispro | $660.78 million (2024) | FDA application facts, recalls, assistance programs, biosimilar status, Part B payment limit, Medicaid spending |
| Nuplazid | 79 | pimavanserin tartrate | $657.83 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Lumigan | 80 | bimatoprost | $647.21 million (2024) | FDA application facts, recalls, Medicaid spending, federal formularies |
| Abilify Maintena | 81 | aripiprazole | $644.23 million (2024) | FDA application facts, assistance programs, Part B payment limit, Medicaid spending, federal formularies |
| Tivicay | 82 | dolutegravir sodium | $629.40 million (2024) | FDA application facts, recalls, Medicaid spending |
| Nurtec ODT | 83 | rimegepant sulfate | $625.23 million (2024) | FDA application facts, recalls, Medicaid spending, federal formularies |
| Tremfya | 84 | guselkumab | $618.78 million (2024) | FDA application facts, recalls, biosimilar status, Part B payment limit, Medicaid spending, federal formularies |
| Zenpep | 86 | pancrelipase lipase, pancrelipase protease, pancrelipase amylase | $597.44 million (2024) | FDA application facts, biosimilar status, Medicaid spending, federal formularies |
| Lynparza | 88 | olaparib | $593.93 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Kesimpta | 90 | ofatumumab | $582.61 million (2024) | FDA application facts, biosimilar status, Medicaid spending, federal formularies |
| Triumeq | 92 | abacavir sulfate, dolutegravir sodium, lamivudine | $565.89 million (2024) | FDA application facts, recalls, Medicaid spending |
| Taltz | 93 | ixekizumab | $564.47 million (2024) | FDA application facts, recalls, assistance programs, biosimilar status, Medicaid spending, federal formularies |
| Albuterol Sulfate HFA | 94 | albuterol sulfate | $552.64 million (2024) | FDA application facts, recalls, Medicaid spending, federal formularies |
| Genvoya | 95 | elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide | $552.01 million (2024) | FDA application facts, assistance programs, Medicaid spending |
| Invega Trinza | 96 | paliperidone palmitate | $549.80 million (2024) | FDA application facts, Part B payment limit, Medicaid spending |
| Descovy | 97 | emtricitabine and tenofovir alafenamide | $544.70 million (2024) | FDA application facts, assistance programs, Medicaid spending |
| Sprycel | 101 | dasatinib | $518.33 million (2024) | FDA application facts, recalls, Medicaid spending, federal formularies |
| Xiidra | 102 | lifitegrast | $505.33 million (2024) | FDA application facts, recalls, Medicaid spending, federal formularies |
| Spiriva Handihaler | 104 | tiotropium bromide | $486.26 million (2024) | FDA application facts, recalls, assistance programs, Medicaid spending, federal formularies |
| Orgovyx | 105 | relugolix | $484.31 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Stiolto Respimat | 109 | tiotropium bromide and olodaterol | $448.59 million (2024) | FDA application facts, assistance programs, Medicaid spending |
| Inlyta | 111 | axitinib | $438.90 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Velphoro | 112 | sucroferric oxyhydroxide | $438.44 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Ubrelvy | 114 | ubrogepant | $429.54 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Tasigna | 115 | nilotinib | $426.96 million (2024) | FDA application facts, recalls, Medicaid spending, federal formularies |
| Multaq | 117 | dronedarone | $414.75 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Kerendia | 119 | finerenone | $396.30 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Trintellix | 121 | vortioxetine | $392.49 million (2024) | FDA application facts, assistance programs, Medicaid spending, federal formularies |
| Combivent Respimat | 122 | ipratropium bromide and albuterol | $387.91 million (2024) | FDA application facts, recalls, assistance programs, Medicaid spending |
| Incruse Ellipta | 124 | umeclidinium | $375.86 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Radicava Ors | 125 | edaravone | $375.71 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Odefsey | 126 | emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide | $375.48 million (2024) | FDA application facts, assistance programs, Medicaid spending |
| Actemra | 127 | tocilizumab | $368.05 million (2024) | FDA application facts, biosimilar status, Part B payment limit, Medicaid spending, federal formularies |
| Acthar | 129 | repository corticotropin | $360.06 million (2024) | FDA application facts, recalls, Part B payment limit, Medicaid spending |
| Gattex | 131 | teduglutide | $357.63 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Synthroid | 133 | levothyroxine sodium | $348.09 million (2024) | FDA application facts, recalls, Medicaid spending, federal formularies |
| Strensiq | 134 | asfotase alfa | $345.97 million (2024) | FDA application facts, biosimilar status, Medicaid spending, federal formularies |
| Korlym | 136 | mifepristone | $341.77 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Ojjaara | 137 | momelotinib | $341.69 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Praluent | 138 | alirocumab | $340.58 million (2024) | FDA application facts, biosimilar status, Medicaid spending, federal formularies |
| Synjardy XR | 141 | empagliflozin, metformin hydrochloride | $320.73 million (2024) | FDA application facts, recalls, assistance programs, Medicaid spending |
| Advair HFA | 142 | fluticasone propionate and salmeterol xinafoate | $320.59 million (2024) | FDA application facts, recalls, Medicaid spending |
| Nucala | 144 | mepolizumab | $317.91 million (2024) | FDA application facts, recalls, biosimilar status, Part B payment limit, Medicaid spending, federal formularies |
| Aimovig | 149 | erenumab-aooe | $305.63 million (2024) | FDA application facts, biosimilar status, Medicaid spending, federal formularies |
| Soliqua | 153 | insulin glargine and lixisenatide | $300.19 million (2024) | FDA application facts, assistance programs, biosimilar status, Medicaid spending, federal formularies |
| Camzyos | 156 | mavacamten | $290.83 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Avonex | 158 | interferon beta-1a | $288.29 million (2024) | FDA application facts, recalls, biosimilar status, Medicaid spending, federal formularies |
| Ninlaro | 160 | ixazomib | $272.70 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Invokana | 161 | canagliflozin | $272.06 million (2024) | FDA application facts, assistance programs, Medicaid spending, federal formularies |
| Aristada | 164 | aripiprazole lauroxil | $269.08 million (2024) | FDA application facts, Part B payment limit, Medicaid spending |
| Caplyta | 165 | lumateperone | $268.48 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Forteo | 166 | teriparatide | $266.35 million (2024) | FDA application facts, assistance programs, Medicaid spending, federal formularies |
| Tibsovo | 167 | ivosidenib | $265.23 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Qulipta | 169 | atogepant | $260.31 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Orserdu | 170 | elacestrant | $258.85 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Emgality | 171 | galcanezumab-gnlm | $258.37 million (2024) | FDA application facts, assistance programs, biosimilar status, Medicaid spending, federal formularies |
| Tymlos | 172 | abaloparatide | $257.64 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Copaxone | 173 | glatiramer acetate | $257.16 million (2024) | FDA application facts, recalls, Medicaid spending |
| Premarin | 176 | estrogens, conjugated | $254.99 million (2024) | FDA application facts, recalls, Part B payment limit, Medicaid spending |
| Rezurock | 183 | belumosudil | $242.93 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Vyvgart | 184 | efgartigimod alfa | $240.80 million (2024) | FDA application facts, biosimilar status, Part B payment limit, Medicaid spending |
| Humulin R | 185 | insulin human | $239.62 million (2024) | FDA application facts, biosimilar status, Part B payment limit, Medicaid spending, federal formularies |
| Lokelma | 186 | sodium zirconium cyclosilicate | $239.00 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Bosulif | 187 | bosutinib | $235.31 million (2024) | FDA application facts, assistance programs, Medicaid spending, federal formularies |
| Ultomiris | 188 | ravulizumab | $232.94 million (2024) | FDA application facts, biosimilar status, Part B payment limit, Medicaid spending |
| Xtampza ER | 189 | oxycodone | $232.75 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Fasenra | 190 | benralizumab | $231.65 million (2024) | FDA application facts, recalls, biosimilar status, Part B payment limit, Medicaid spending, federal formularies |
| Zejula | 194 | niraparib | $224.14 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Takhzyro | 195 | lanadelumab-flyo | $223.00 million (2024) | FDA application facts, biosimilar status, Part B payment limit, Medicaid spending, federal formularies |
| Briviact | 197 | brivaracetam | $219.77 million (2024) | FDA application facts, recalls, Medicaid spending, federal formularies |
| Benlysta | 199 | belimumab | $216.81 million (2024) | FDA application facts, recalls, biosimilar status, Part B payment limit, Medicaid spending, federal formularies |
| Teriparatide | 201 | teriparatide | $212.62 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Krystexxa | 202 | pegloticase | $212.35 million (2024) | FDA application facts, biosimilar status, Part B payment limit, Medicaid spending, federal formularies |
| Cabenuva | 203 | cabotegravir and rilpivirine | $211.61 million (2024) | FDA application facts, Part B payment limit, Medicaid spending |
| Epidiolex | 206 | cannabidiol | $207.44 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Mekinist | 207 | trametinib | $207.01 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Welireg | 208 | belzutifan | $205.46 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Xigduo XR | 210 | dapagliflozin and metformin hydrochloride | $203.53 million (2024) | FDA application facts, recalls, assistance programs, Medicaid spending, federal formularies |
| Victoza 3-Pak | 211 | liraglutide | $203.06 million (2024) | FDA application facts, recalls, Medicaid spending, federal formularies |
| Jaypirca | 213 | pirtobrutinib | $200.56 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Arnuity Ellipta | 214 | fluticasone furoate | $199.86 million (2024) | FDA application facts, recalls, Medicaid spending, federal formularies |
| Scemblix | 218 | asciminib | $197.19 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Wixela Inhub | 220 | fluticasone propionate and salmeterol | $196.50 million (2024) | FDA application facts, recalls, Medicaid spending |
| Soliris | 221 | eculizumab | $196.19 million (2024) | FDA application facts, recalls, biosimilar status, Part B payment limit, Medicaid spending, federal formularies |
| Ocrevus | 222 | ocrelizumab | $195.07 million (2024) | FDA application facts, assistance programs, biosimilar status, Part B payment limit, Medicaid spending, federal formularies |
| Vumerity | 225 | diroximel fumarate | $189.81 million (2024) | FDA application facts, recalls, Medicaid spending, federal formularies |
| Metformin HCl | 226 | metformin hcl | $188.06 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Arikayce | 227 | amikacin | $187.06 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Simponi | 230 | golimumab | $184.71 million (2024) | FDA application facts, biosimilar status, Medicaid spending, federal formularies |
| Truqap | 232 | capivasertib | $184.17 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Tezspire | 233 | tezepelumab-ekko | $183.77 million (2024) | FDA application facts, biosimilar status, Part B payment limit, Medicaid spending, federal formularies |
| Synjardy | 235 | empagliflozin and metformin hydrochloride | $180.25 million (2024) | FDA application facts, recalls, assistance programs, Medicaid spending |
| Mavenclad | 237 | cladribine | $178.19 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Winrevair | 239 | sotatercept-csrk | $177.62 million (2024) | FDA application facts, biosimilar status, Medicaid spending, federal formularies |
| Tafinlar | 241 | dabrafenib | $173.89 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Kevzara | 243 | sarilumab | $172.20 million (2024) | FDA application facts, biosimilar status, Medicaid spending, federal formularies |
| Rhopressa | 245 | netarsudil | $168.05 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Trazodone HCl | 248 | trazodone hcl | $165.40 million (2024) | FDA application facts, recalls, Medicaid spending, federal formularies |
| Xcopri | 251 | cenobamate | $164.70 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Lupron Depot | 252 | leuprolide acetate | $164.00 million (2024) | FDA application facts, recalls, Part B payment limit, Medicaid spending |
| Tecfidera | 253 | dimethyl fumarate | $162.84 million (2024) | FDA application facts, recalls, Medicaid spending, federal formularies |
| Combigan | 254 | brimonidine tartrate, timolol maleate | $162.25 million (2024) | FDA application facts, recalls, Medicaid spending |
| Dulera | 255 | mometasone furoate and formoterol fumarate dihydrate | $162.08 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Belbuca | 256 | buprenorphine hydrochloride | $160.14 million (2024) | FDA application facts, recalls, Medicaid spending |
| Ayvakit | 258 | avapritinib | $160.03 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Prednisolone Acetate | 266 | prednisolone acetate | $155.04 million (2024) | FDA application facts, recalls, Medicaid spending, federal formularies |
| Evrysdi | 267 | risdiplam | $154.53 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Insulin Lispro | 268 | insulin lispro | $154.43 million (2024) | FDA application facts, recalls, assistance programs, biosimilar status, Part B payment limit, Medicaid spending |
| Dificid | 271 | fidaxomicin | $153.76 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Lumakras | 272 | sotorasib | $153.62 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Ventolin HFA | 274 | albuterol sulfate | $152.86 million (2024) | FDA application facts, recalls, Medicaid spending, federal formularies |
| Tepezza | 275 | teprotumumab | $151.91 million (2024) | FDA application facts, biosimilar status, Part B payment limit, Medicaid spending |
| Belsomra | 276 | suvorexant | $150.18 million (2024) | FDA application facts, recalls, Medicaid spending, federal formularies |
| Aubagio | 277 | teriflunomide | $148.48 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Sertraline HCl | 278 | sertraline hcl | $147.54 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Glyxambi | 284 | empagliflozin and linagliptin | $141.06 million (2024) | FDA application facts, recalls, assistance programs, Medicaid spending |
| Amvuttra | 286 | vutrisiran | $140.92 million (2024) | FDA application facts, Part B payment limit, Medicaid spending, federal formularies |
| Keytruda | 287 | pembrolizumab | $140.06 million (2024) | FDA application facts, assistance programs, biosimilar status, Part B payment limit, Medicaid spending, federal formularies |
| Tukysa | 288 | tucatinib | $139.35 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Braftovi | 289 | encorafenib | $138.10 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Fruzaqla | 290 | fruquintinib | $137.47 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Relistor | 293 | methylnaltrexone bromide | $134.57 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Varenicline Tartrate | 296 | varenicline tartrate | $132.50 million (2024) | FDA application facts, recalls, Medicaid spending |
| Wakix | 297 | pitolisant hydrochloride | $132.46 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Auryxia | 298 | ferric citrate | $131.54 million (2024) | FDA application facts, recalls, Medicaid spending |
| Vyzulta | 304 | latanoprostene bunod | $128.29 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Lybalvi | 308 | olanzapine and samidorphan l-malate | $127.26 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Simvastatin | 311 | simvastatin | $126.43 million (2024) | FDA application facts, recalls, assistance programs, Medicaid spending, federal formularies |
| Vyvgart Hytrulo | 312 | efgartigimod alfa and hyaluronidase (human recombinant) | $126.10 million (2024) | FDA application facts, biosimilar status, Part B payment limit, Medicaid spending |
| Tabrecta | 314 | capmatinib | $124.11 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Trulance | 315 | plecanatide | $123.24 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Pradaxa | 316 | dabigatran etexilate mesylate | $123.18 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Cresemba | 317 | isavuconazonium sulfate | $123.03 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Omeprazole-Sodium Bicarbonate | 318 | omeprazole | $122.38 million (2024) | FDA application facts, assistance programs, Medicaid spending, federal formularies |
| Botox | 319 | onabotulinumtoxina | $122.28 million (2024) | FDA application facts, recalls, biosimilar status, Part B payment limit, Medicaid spending, federal formularies |
| Xphozah | 320 | tenapanor | $121.51 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Levemir | 321 | insulin detemir | $121.31 million (2024) | FDA application facts, biosimilar status, Medicaid spending |
| Prevymis | 324 | letermovir | $120.45 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Fotivda | 327 | tivozanib | $118.90 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Remicade | 328 | infliximab | $118.80 million (2024) | FDA application facts, biosimilar status, Part B payment limit, Medicaid spending, federal formularies |
| Jublia | 329 | efinaconazole | $118.60 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Venlafaxine HCl ER | 330 | venlafaxine hcl er | $118.52 million (2024) | FDA application facts, recalls, Medicaid spending, federal formularies |
| Erivedge | 331 | vismodegib | $116.77 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Lorbrena | 332 | lorlatinib | $116.73 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Miebo | 333 | perfluorohexyloctane | $116.31 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Atrovent HFA | 335 | ipratropium bromide | $115.31 million (2024) | FDA application facts, assistance programs, Medicaid spending, federal formularies |
| Risperdal Consta | 337 | risperidone | $114.77 million (2024) | FDA application facts, recalls, assistance programs, Part B payment limit, Medicaid spending, federal formularies |
| Isentress | 339 | raltegravir | $112.74 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Diclofenac Epolamine | 340 | diclofenac epolamine | $112.43 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Buspirone HCl | 343 | buspirone hydrochloride | $111.22 million (2024) | FDA application facts, recalls, Medicaid spending, federal formularies |
| Vonjo | 345 | pacritinib | $110.82 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Piqray | 346 | alpelisib | $109.76 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Serostim | 347 | somatropin | $109.52 million (2024) | FDA application facts, biosimilar status, Medicaid spending, federal formularies |
| Invega Hafyera | 348 | paliperidone palmitate | $109.43 million (2024) | FDA application facts, Part B payment limit, Medicaid spending |
| Sucraid | 350 | sacrosidase | $107.66 million (2024) | FDA application facts, biosimilar status, federal formularies |
| Valacyclovir | 352 | valacyclovir | $106.80 million (2024) | FDA application facts, recalls, Medicaid spending, federal formularies |
| Nuzyra | 353 | omadacycline | $106.62 million (2024) | FDA application facts, Part B payment limit, Medicaid spending, federal formularies |
| Xospata | 354 | gilteritinib | $106.44 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Opzelura | 355 | ruxolitinib | $105.90 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Rebif | 356 | interferon beta-1a | $105.38 million (2024) | FDA application facts, biosimilar status, Medicaid spending, federal formularies |
| Jynarque | 358 | tolvaptan | $103.48 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Darzalex Faspro | 360 | daratumumab and hyaluronidase-fihj (human recombinant) | $102.72 million (2024) | FDA application facts, biosimilar status, Part B payment limit, Medicaid spending |
| Skyclarys | 362 | omaveloxolone | $101.27 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Gocovri | 363 | amantadine | $99.84 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Trijardy XR | 364 | empagliflozin, linagliptin, metformin hydrochloride | $99.14 million (2024) | FDA application facts, assistance programs, Medicaid spending |
| Nifedipine ER | 365 | nifedipine | $99.06 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Xpovio | 366 | selinexor | $98.22 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Stivarga | 371 | regorafenib | $96.42 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Mektovi | 374 | binimetinib | $96.18 million (2024) | FDA application facts, recalls, Medicaid spending, federal formularies |
| Evenity | 380 | romosozumab-aqqg | $92.58 million (2024) | FDA application facts, recalls, biosimilar status, Part B payment limit, Medicaid spending, federal formularies |
| Fentanyl | 381 | fentanyl | $92.39 million (2024) | FDA application facts, Medicaid spending, federal formularies |
| Betaseron | 382 | interferon beta-1b | $92.24 million (2024) | FDA application facts, biosimilar status, Medicaid spending, federal formularies |
How these pages are built
A page exists only when Part D spending and at least three other federal data layers hold facts for the medicine, one of them label events, a generic-entry bound or recalls. Medicines below that bar get no page rather than a thin one. Every figure carries its source and date. Where every figure comes from. Licence the data.
For developers: every page as data
The index lists every file, including one dossier per medicine on this list, each with receipts.
Example file: https://omnirx.org/api/v1/index.json
The licence page sets out what a data licence covers, and the API page documents these files.
Evaluation files with receipts; contract may change; not clinical advice.